TRBC1-targeting antibody–drug conjugates for the treatment of T cell cancersTushar D. Nichakawade, Suman Paul, Jiaxin Ge et al.|Nature|2024Cited by 43
Loncastuximab in High-Risk and Heavily-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real World Analysis from 21 US CentersEmily C. Ayers, Narendranath Epperla, Viktoriya Zelikson et al.|Blood|2023Cited by 10
Loncastuximab in high-risk and heavily pretreated relapsed / refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centersViktoriya Zelikson, Emily C. Ayers, Ashwath Gurumurthi et al.|Haematologica|2024Cited by 6
Detection of Human Brain Cancers using Genomic and Immune Cell Characterization of Cerebrospinal Fluid through CSF-BAMAlexander H. Pearlman, Chetan Bettegowda, Yuxuan Wang et al.|Cancer Discovery|2025Cited by 4
TRBC2-targeting antibody–drug conjugates for the treatment of T cell cancersJiaxin Ge, Joshua Urban, Sarah R. DiNapoli et al.|Nature Cancer|2025Cited by 1